Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00587015 · ClinicalTrials.gov registry record · Phase 1
A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)
A Phase 1 study, sponsored by MedImmune.
- Terminated
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
NCT00587015 is a Phase 1 study that was terminated before completion, run by MedImmune. The registered enrollment target is 50 participants.
The verdict
NCT00587015, a Phase 1 study, was terminated before completion, sponsored by MedImmune.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
Study Summary
A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
Interventions
- DRUG CAT-8015
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2007-08 |
| Est. Completion | 2009-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00587015
The ClinicalTrials.gov registry entry for NCT00587015 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is MedImmune, which has 210 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CAT-8015 is the first listed.
NCT00587015 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00587015 about?
NCT00587015 is a clinical study titled "A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's Lymphoma (NHL)". A dose-escalation study to estimate the maximum tolerated dose(MTD) of CAT-8015 that can be safely administered to a patient.
What is the current status of trial NCT00587015?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2007-08. Estimated completion is 2009-10.
What interventions are being tested in trial NCT00587015?
The interventions under investigation include: CAT-8015 (DRUG).
Who is sponsoring clinical trial NCT00587015?
This trial is sponsored by MedImmune, which has 210 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.